Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ASSEMBLY BIOSCIENCES, INC.

Get SEC filing alerts via email and in your feed for ASSEMBLY BIOSCIENCES, INC.

ASMB

ASSEMBLY BIOSCIENCES, INC.

About ASSEMBLY BIOSCIENCES, INC.

Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for serious viral diseases. Its pipeline includes clinical-stage therapies targeting recurrent genital herpes, hepatitis delta virus (HDV), and hepatitis B virus (HBV). With significant market opportunities, Assembly aims to address unmet medical needs through collaborations, notably with Gilead Sciences. The company is advancing multiple candidates towards clinical readouts, enhancing treatment options for patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ASSEMBLY BIOSCIENCES, INC.

1
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports Q1 2026 Financial Results with $8.2M Collaboration Revenue

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports 154% Revenue Increase to $72.3 Million in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports 58% Increase in Collaboration Revenue for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports 13% Revenue Growth in Q2 2025, Net Loss of $10.2 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports 63% Revenue Growth to $9.4M in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports $28.5M Collaboration Revenue and $40.2M Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ASSEMBLY BIOSCIENCES, INC. Assembly Biosciences Reports Improved Financials, Collaboration Revenue Growth in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments